5/15/2013 7:59:30 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial results for the quarter ended March 31, 2013.
“Our next objective in Idera’s autoimmune disease program is to initiate a Phase 2 study of IMO-8400, a first-in-class TLR7, 8 and 9 antagonist, in patients with moderate-to-severe plaque psoriasis during the current quarter.
Help employers find you! Check out all the jobs and post your resume.
comments powered by